Kintara Therapeutics, Inc. (KTRA)
- Previous Close
0.1327 - Open
0.1306 - Bid 0.1368 x 500
- Ask 0.1388 x 400
- Day's Range
0.1299 - 0.1429 - 52 Week Range
0.0810 - 5.9800 - Volume
5,815,467 - Avg. Volume
14,070,212 - Market Cap (intraday)
5.36M - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-5.2200 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
www.kintara.comRecent News: KTRA
Performance Overview: KTRA
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KTRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KTRA
Valuation Measures
Market Cap
5.36M
Enterprise Value
14.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.41
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-112.61%
Return on Equity (ttm)
-329.00%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.77M
Diluted EPS (ttm)
-5.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
772k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.16M